Shares of Advaxis Inc. (NASDAQ:ADXS) traded down 4.1% during trading on Wednesday . The stock traded as low as $8.29 and last traded at $8.32, with a volume of 492,083 shares. The stock had previously closed at $8.68.

Several analysts recently commented on the company. FBR & Co reaffirmed an “outperform” rating and issued a $34.00 price objective on shares of Advaxis in a report on Thursday, July 7th. HC Wainwright reaffirmed a “buy” rating on shares of Advaxis in a report on Wednesday, June 29th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Advaxis in a report on Friday, June 10th. Six equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average price target of $24.80.

The stock’s 50 day moving average is $8.55 and its 200-day moving average is $8.09. The company’s market capitalization is $286.10 million.

In other news, Director Thomas J. Mckearn sold 4,100 shares of the stock in a transaction on Friday, May 13th. The stock was sold at an average price of $7.45, for a total transaction of $30,545.00. Following the completion of the sale, the director now owns 82,120 shares in the company, valued at approximately $611,794. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Daniel O’connor sold 8,237 shares of the stock in a transaction on Monday, May 2nd. The shares were sold at an average price of $7.51, for a total value of $61,859.87. Following the sale, the chief executive officer now owns 316,661 shares of the company’s stock, valued at approximately $2,378,124.11. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Advaxis stock. Oxford Asset Management acquired a new stake in shares of Advaxis Inc. (NASDAQ:ADXS) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 146,282 shares of the biotechnology company’s stock, valued at approximately $1,502,000. Oxford Asset Management owned about 0.43% of Advaxis at the end of the most recent quarter.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.